FDA Approves New Drug for Advanced Pancreatic Cancer

The Food and Drug Administration (FDA) has approved a new drug from Revolution Medicines, named Rasonque or daraxonrasib. This drug presents a new hope for patients with advanced pancreatic cancer, particularly those who have previously undergone treatments like chemotherapy. According to the FDA, Rasonque was shown to significantly improve patient outcomes.

In a late-stage trial involving 500 participants, patients receiving Rasonque alongside chemotherapy lived an average of 13.2 months. This is approximately double the survival time compared to those receiving only chemotherapy. Dr. Rachna Shroff, from the University of Arizona Cancer Center, expressed her emotional response to these findings, citing the groundbreaking impact of the drug on pancreatic cancer treatment.

**Potential Side Effects**

Despite its revolutionary approach, Rasonque does come with side effects. These include severe rashes, mouth and throat sores, vomiting, and diarrhea. Former Senator Ben Sasse, who participated in a clinical trial, described the rash side effect as severe in a podcast interview.

**Targeting KRAS Mutation**

Rasonque effectively targets a mutation in the KRAS gene, prevalent in almost all pancreatic cancers and several other cancers, including lung and colorectal cancers. The KRAS gene regulates cell growth, and mutations cause unchecked cell proliferation. While researchers have aimed to target this mutation for years with little success, Rasonque has proven effective.

**Broader Implications**

Channing Der, a pharmacologist, highlighted the FDA’s approval as monumental in combating pancreatic cancer. Pancreatic cancer ranks as the third leading cause of cancer-related deaths in the U.S., with over 67,000 expected diagnoses this year. Early detection is challenging, as there is no screening, and initial symptoms are often vague, contributing to the disease’s advanced stage diagnosis and low survival rates.

More than 2,000 patients have accessed the drug through an expanded access program initiated by Revolution Medicines. However, the cost of Rasonque remains undisclosed.